WO2011096665A2 - Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor - Google Patents

Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor Download PDF

Info

Publication number
WO2011096665A2
WO2011096665A2 PCT/KR2011/000541 KR2011000541W WO2011096665A2 WO 2011096665 A2 WO2011096665 A2 WO 2011096665A2 KR 2011000541 W KR2011000541 W KR 2011000541W WO 2011096665 A2 WO2011096665 A2 WO 2011096665A2
Authority
WO
WIPO (PCT)
Prior art keywords
complex formulation
hmg
aspirin
coa reductase
reductase inhibitor
Prior art date
Application number
PCT/KR2011/000541
Other languages
French (fr)
Other versions
WO2011096665A3 (en
Inventor
Jong Soo Woo
Jae Hyun Park
Yong Il Kim
Young Jun Na
Jun Young Choi
Yun Ah Lee
Original Assignee
Hanmi Holdings Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co., Ltd. filed Critical Hanmi Holdings Co., Ltd.
Priority to JP2012551908A priority Critical patent/JP2013518873A/en
Priority to CN2011800078123A priority patent/CN102740857A/en
Priority to EP11739961.8A priority patent/EP2531199A4/en
Priority to US13/576,585 priority patent/US20120301549A1/en
Publication of WO2011096665A2 publication Critical patent/WO2011096665A2/en
Publication of WO2011096665A3 publication Critical patent/WO2011096665A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a complex formulation for the prevention or treatment of cardiovascular diseases, which comprises a) aspirin coated with a barrier containing a hydrophobic additive, and b) an HMG-CoA reductase inhibitor.
  • Hyperlipidemia is the condition of abnormally elevated levels of lipids such as cholesterols, triglycerides, and others, in the plasma. Hyperlipidemia, particularly hypercholesterolemia, induces arterial thrombosis, resulting in arteriosclerosis which is thick accumulation of lipids within the blood vessel. It is clinically important since it contributes to cardiovascular diseases such as ischemic heart disease, angina pectoris, and myocardial infarction. The prevention of arteriosclerosis may be achievable by way of the treatment of hypercholesterolemia highly associated therewith.
  • HMG-CoA reductase inhibitors have been used to treat hyperlipidemia. Such compounds have been known to lower total cholesterol and LDL-cholesterol in human body and to elevate HDL-cholesterol in some individuals. They inhibit HMG-CoA reductase involved in the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol. This process increases receptors of LDLs which induce arteriosclerosis, leading to the decrease in the concentration of LDL within blood (Grundy S. M., N. Engl. J. Med., 319(l):24-32, 25-26, 31(1988). Examples of HMG-CoA reductase inhibitors include mevastatin (U.S.
  • lovastatin also called mevinolin; U.S. Pat. No. 4, ,231,227)
  • pravastatin U.S. Pat. Nos. 4,346,227 and 4,410,629
  • pravastatin lactone U.S. Pat. No. 4,448,979
  • velostatin also called synvinolin; U.S. Pat. Nos. 4,448,784 and 4,450,171
  • simvastatin also called mevinolin; U.S. Pat. Nos. 4,448,784 and 4,450,171
  • simvastatin rivastatin
  • fluvastatin atorvastatin
  • rosuvastatin cerivastain
  • Thrombus is achieved via the interaction of platelets and plasma coagulation factor in an injured vessel, which also induces arteriosclerosis.
  • Aspirin is used as an antipyretic to reduce fever, as an analgesic to relieve minor aches and pains, and as an agent to prevent arterial thrombosis.
  • Aspirin also known as acetylsalicylic acid
  • Aspirin irreversibly acetylates cyclooxygenase, thereby inhibiting the production of thromboxane A2 (TXA2), which is synthesized by platelets to promote platelet aggregation. This blocks platelet aggregation in blood to decrease platelets.
  • the combination of an HMG-CoA reductase inhibitor and aspirin may be useful in treating various cardiovascular diseases by providing each effect of the drugs at the same time, as well as in treating a cardiovascular disease effectively by providing synergistic effects of the drugs.
  • the complex formulation comprising the combination of said drugs may allow for greater ease of administration than the individual administrations of said drugs.
  • HMG-CoA reductase inhibitors exhibit poor bioavailability and are absorbed in the gastrointestinal tract, and thus it would be beneficial to be rapidly released in the gastrointestinal tract. Meanwhile, aspirin may exhibit adverse side effects, e.g., gastric ulcer or gastric bleeding when it is released within the gastrointestinal tract, and may interact adversely with HMG-CoA reductase inhibitors when both are released at the same time within the gastrointestinal tract. Thus, it needs to render aspirin to be released within not the stomach but the small intestine.
  • the present inventors have filed an application for a formulation comprising an aspirin-containing granule and an HMG-CoA reductase inhibitor-containing granule (Korean Application Publication No. 2009-0030452). However, during storage, aspirin in the formulation degrades into salicylic acid by hydrolysis, and the resulting salicylic acid may degrade HMG-CoA reductase inhibitors which are unstable under acidic conditions.
  • the present inventors have found that the deterioration in the stability of HMG-CoA reductase caused by salicylic acid can be prevented by coating aspirin with a barrier containing a hydrophobic additive.
  • a complex formulation for the prevention or treatment of cardiovascular diseases which has improved storage stability by preventing the deterioration in the stability of of HMG- CoA reductase inhibitors which is caused by salicylic acid.
  • a complex formulation for the prevention or treatment of cardiovascular diseases comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor.
  • the barrier comprises the hydrophobic additive in an amount of 3.8-60% by weight based on the total weight of the barrier.
  • the complex formulation of the present invention exhibits excellent effect on the prevention and treatment of cardiovascular diseases, exerting improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase inhibitors which is caused by salicylic acid, thereby being useful for the prevention and treatment of cardiovascular diseases.
  • Fig. 1 the stability test of the complex formulation of the present invention after 4 months under accelerated conditions, showing the amounts of atorvastatin lactone and salicylic acid;
  • Fig. 2 the stability test of the complex formulation of the present invention after 4 months under accelerated conditions, showing the amounts of rosuvastatin lactone and salicylic acid;
  • Fig. 3 the stability test of the complex formulation of the present invention after 4 months under accelerated conditions depending on the amount of a hydrophobic additive, showing the amounts of atorvastatin lactone and salicylic acid;
  • Fig. 4 the dissolution rates of coated aspirin pellets of Examples 2 and 4, 'Aspirin Protect ® ', and 'Astrix ® ' for 1 hour depending on pH;
  • Fig. 5 the change of dissolution rate of the complex formulation of the present invention for 1 hour depending on the amount of a hydrophobic additive.
  • the present invention provides a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing about 3.8-60% of a hydrophobic additive by weight based on the total amount of the barrier, as a 1 st pharmacologically active ingredient; and b) an HMG- CoA reductase inhibitor as a 2 nd pharmacologically active ingredient.
  • a complex formulation for the prevention or treatment of cardiovascular diseases comprising: a) aspirin coated with a barrier containing about 3.8-60% of a hydrophobic additive by weight based on the total amount of the barrier, as a 1 st pharmacologically active ingredient; and b) an HMG- CoA reductase inhibitor as a 2 nd pharmacologically active ingredient.
  • Aspirin is used as 1 st pharmacologically active ingredient in the present invention so as to prevent and treat arterial thrombosis by blocking the platelet aggregation in blood. It may be employed in an amount of lOmg to 2g per the formulation and in the form of pellets or granules.
  • a hydrophobic additive is used in the present invention so as to block the migration of salicylic acids into the granule layer containing an HMG-CoA reductase inhibitor, the use of which is different to enteric coating bases for releasing drugs depending on pH.
  • an HMG-CoA reductase inhibitor the use of which is different to enteric coating bases for releasing drugs depending on pH.
  • water- soluble and hydrophilic aspirin or salicylic acid derived from aspirin migrates to the coating layer, consequently penetrating the layer.
  • a hydrophobic additive is added to the coating layer, it is possible to prevent the migration of the drug to the coating layer and the consequent adverse influence of said drug on HMC-CoA reductase inhibitors.
  • Such hydrophobic additive is a coating base which is irrelevant to pH and is not used for sustained- or delayed-release.
  • hydrophobic additives examples include waxes such as carnauba wax, glyceryl monostearate, glyceryl monooleate and beeswax; and synthetic or semisynthetic hydrophobic polymers such as ethyl cellulose, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer, polyvinyl chloride, polyvinyl acetate and cellulose acetate.
  • waxes such as carnauba wax, glyceryl monostearate, glyceryl monooleate and beeswax
  • synthetic or semisynthetic hydrophobic polymers such as ethyl cellulose, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer, polyvinyl chloride, polyvinyl acetate and cellulose acetate.
  • the barrier containing such hydrophobic additive may further comprise a plasticizer such as triethyl citrate, polyethylene glycol, propylene glycol, acetylated monoglyceride, diethyl phthalate and dibutyl sebacate, and may also comprise additional coating bases commonly used in pharmaceutical industry such as HPMC, HPC, polyvinyl alcohol, and others.
  • talc, titanium dioxide, and others may be used to prevent the adhesion of pellets during coating procedure.
  • the hydrophobic additive may be used in an amount of about 3.8% or more by weight based on the total amount of the barrier, and it is preferred not to exceed about 60% by weight. When the amount exceeds 60% by weight based on the total amount of the barrier, the release of drug would be excessively delayed.
  • HMG-CoA reductase inhibitor An HMG-CoA reductase inhibitor is used as a 2 nd pharmacologically active ingredient so as to prevent or treat hyperlipidemia and arteriosclerosis by lowering the concentration of lipoproteins or lipids.
  • HMG-CoA reductase inhibitors include mevastatin, rosuvastatin, atorvastatin, lovastatin, pravastatin, pravastatin lactone, pitavastatin, bervastatin, velostatin, simvastatin, rivastatin, fluvastatin, cerivastatin or isomers or salts and combinations thereof.
  • the HMG-CoA reductase inhibitor may be employed in an amount of 5mg to
  • the complex formulation of the present invention may further comprise an enteric coating layer between the aspirin core and the hydrophobic barrier.
  • the enteric coating base is not used for the purpose of preventing the interaction of the released salicylic acid and HMG-CoA reductase inhibitors.
  • the effects of enteric coating base are not enough to inhibit the action of released salicylic acid as evidenced by the experiments of the present invention.
  • the main objective of use of the enteric coating base is to allow aspirin to be released into not the stomach of a low pH but the small intestine, particularly the upper small intestine, of high pH.
  • enteric coating bases include hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, methacrylic acid copolymer, and hydroxypropyl methylcellulose acetate succinate.
  • the coating base may be used in a weight ratio of 0.1 to 0.5 based on 1 weight of the core.
  • the complex formulation of the present invention may further comprise a stabilizing agent for enhancement stability of HMG-CoA reductase inhibitor
  • stabilizing agents include antioxidants such as tocopherol, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ascorbic acid and erythorbic acid; minerals such as CaC0 3 , MgC0 3 , NaHC0 3 , KH 2 P0 4 and K 2 HP0 3 ; basic additives such as meglumine, arginine and glycine; and other stabilizing agents such as organic acids, e.g., citric acid and fumaric acid, or salts thereof.
  • antioxidants such as tocopherol, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ascorbic acid and erythorbic acid
  • minerals such as CaC0 3 , MgC0 3 , NaHC0 3 , KH 2 P0 4 and K 2 HP0 3
  • the complex formulation of the present invention may be prepared by the method comprising: (1) preparing an aspirin granule or pellet which is coated with a barrier containing a hydrophobic additive; (2) preparing an HMG-CoA reductase inhibitor granule or pellet; and (3) filling a capsule with the aspirin granule or pellet and the HMG-CoA reductase inhibitor granule or pellet, prepared in steps (1) and (2), or compressing said granules or pellets.
  • the average diameter of the aspirin granule or pellet prepared in step (1) is preferably 1,200 ⁇ or less, more preferably 1,000 ⁇ or less.
  • the mixing degree between both pharmacologically active ingredients become poor, which may adversely affect the homogeneity of the complex formulation in a form of tablets.
  • the present invention also provides a method of preventing or treating cardiovascular diseases, which comprises administering the complex formulation of the present invention to a mammal in need thereof.
  • the complex formulation of the present invention may be administered orally as an active ingredient in an effective amount ranging from about 0.01 to 100 mg/kg, preferably 0.2 to 50 mg/kg body weight per day in case of mammals including human in a single dose or in divided doses.
  • the dosage of the active ingredient may be adjusted in light of various relevant factors such as the condition of the subject to be treated, type and seriousness of illness, administration rate, and opinion of doctor. In certain cases, an amount less than the above dosage may be suitable. An amount greater than the above dosage may be used unless it causes deleterious side effects and such amount can be administered in divided doses per day.
  • Example 1 Preparation of aspirin pellet and granule
  • aspirin (Spectrum Chemical, US), hydroxypropyl methylcellulose (HPMC; Shinetsu, Japan), citric acid and talc (Nippon talc, Japan) were dissolved and dispersed in a mixed solution of water and ethanol to prepare an aspirin-containing coating solution.
  • the coating solution was sprayed while fluidizing microcrystalline spherical beads (cellet; Pharmatrans) using a fluidized bed spray coater (NQ-125, Fuji Paudal, Japan), to prepare an aspirin pellet.
  • Example 2 the aspirin pellet or granule of Example 1 was coated with barriers containing various compositions of hydrophobic additives. Specifically, HPMC, acetylated monoglyceride (myvacet ® ; Kerry bio-science, US), talc, titanium dioxide (Ti0 2 ), and hydrophobic additives (camauba wax or ethyl cellulose (EC, Colorcon)) were dissolved and dispersed in a mixed solution of water and ethahol to prepare barrier coating solutions.
  • HPMC acetylated monoglyceride
  • talc titanium dioxide
  • Ti0 2 titanium dioxide
  • hydrophobic additives camauba wax or ethyl cellulose (EC, Colorcon)
  • each coating solution was sprayed while fluidizing the aspirin pellet or granule (cellet; Pharmatrans) using a fluidized bed spray coater (NQ-125, Fuji Paudal, Japan), to prepare barrier-coated aspirin pellets.
  • the aspirin pellet or granule of Example 1 was coated with coating solutions shown in Table 3. Specifically, HPMC or HPMCP (hydroxypropyl methylcellulose phthalate; Shinetsu, Japan), Myvacet ® , talc and titanium dioxide were dissolved and dispersed in a mixed solution of water and ethanol or acetone, to prepare barrier coating solutions. Then, the each coating solution was sprayed while fluidizing the aspirin pellet or granule of Example 1 using a fluidized bed spray coater (NQ-125, Fuji Paudal, Japan), to prepare conventional barrier-coated or enteric-coated aspirin pellets or granules.
  • HPMC or HPMCP hydroxypropyl methylcellulose phthalate; Shinetsu, Japan
  • Myvacet ® hydroxypropyl methylcellulose phthalate
  • talc talc
  • titanium dioxide talc and titanium dioxide
  • Example 8 and Comparative Example 4 Coating with barrier containing hydrophobic additive (2)
  • Example ⁇ 1-1> and Comparative Example 3 were coated with barriers containing a hydrophobic additive as shown in Table 4, respectively, according to same method with Exampl
  • Granules containing various HMG-CoA reductase inhibitors were prepared.
  • atorvastatin calcium (TEVA, Israel) was mixed with Avicel ® , croscarmellose sodium (DMV international), lactose(DMV international) and magnesium carbonate, and kneaded with a binding solution in which HPC and polysorbate 80 are dissolved in water. The combined product was dried, and sieved through a 30 mesh sieve to prepare an atorvastatin-containing granule.
  • Example ⁇ 9-l> The procedure of Example ⁇ 9-l> was repeated except for using rosuvastatin calcium (MSN, India) instead of atorvastatin calcium to obtain a rosuvastatin- containing granule.
  • complex formulations containing aspirin and HMG-CoA reductase inhibitor were prepared in accordance with Table 6. Specifically, granules (or pellets) corresponding to aspirin 100 mg and HMG-CoA reductase inhibitor 10 mg, respectively, were filled into size #0 capsules to obtain complex formulations.
  • Comparative Formulation Examples 5 and 6 are formulations prepared by filling only HMC-CoA reductase inhibitors into size #0 capsules.
  • the complex formulations prepared from Formulation Examples 1 to 8 and Comparative Formulation Examples 1 to 7 were each packaged together with lg of silica gel in an HDPE bottle and tested for their stability for 2 and 4 months by storing under accelerated conditions (45°C, 75% RH).
  • aspirin the content of released salicylic acid was measured in accordance with the USP (United States Pharmacopeia) specification for 'aspirin tablet' and 'aspirin delayed-release capsule'.
  • atorvastatin the contents of a representative acid hydrolyzate, i.e., atorvastatin lactone and total related compounds were measured.
  • Figs. 1 and 2 are graphs showing the stabilities after 4 months under accelerated conditions
  • Fig. 3 is a graph showing the stability after 4 months under accelerated conditions depending on the amount of a hydrophobic additive.
  • Comparative Formulation Examples 1 and 2 using conventional coating bases, HPMC, and Comparative Formulation Example 3 using an enteric coating base, HPMCP showed relatively stable appearances, but did not completely prevent the effects of released salicylic acid on an HMG-CoA reductase inhibitor. That is, salicylic acids released from aspirin hinder the stability of atorvastatin, and consequently its stability became poor compared to that of Comparative Formulation Example 5 using only atorvastatin. In particular, it was shown that much amounts of atorvastatin lactone and total related compounds were produced.
  • Formulation Examples 1 to 7 containing aspirin coated with EC or carnauba wax as a hydrophobic barrier showed highly improved stability than Comparative Formulation Examples.
  • Such phenomenon was similarly observed in other HMG-CoA reductase inhibitor, rosuvastatin.
  • a complex formulation comprising ah aspirin granule coated with a hydrophobic additive-containing barrier can provide improved storage stability, such formulation being utilized as a stable and excellent agent for treating hypertension and hypercholesterolemia.
  • the aspirin pellets of Examples 2 to 5 and Comparative Examples 1 and 4 were placed into capsules (e.g., gelation capsule; Capsugel) in an amount corresponding to lOOmg of aspirin, respectively, and tested for the dissolution in artificial gastric juice (pH 1.2) and in artificial enteric juice (phosphate buffer, pH 6.8) by 10 rpm according to USP apparatus 1 (basket).
  • capsules e.g., gelation capsule; Capsugel
  • the analysis was carried out in accordance with the USP (United States Pharmacopeia) specification for 'aspirin tablet' and 'aspirin delayed-release capsule'.
  • Fig. 4 was plotted based on the results of Tables 9 and 10. As shown in Fig. 4, the dissolution rates of 'Aspirin Protect ® ' and 'Astrix ® ' were significantly changed with pH, whereas the complex formulations of the present invention which contains aspirin coated with a hydrophobic additive-containing barrier showed no changes in dissolution rate with pH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia.

Description

COMPLEX FORMULATION COMPRISING ASPIRIN COATED WITH BARRIER CONTAINING HYDROPHOBIC ADDITIVE, AND HMG-COA
REDUCTASE INHIBITOR FIELD OF THE INVENTION
The present invention relates to a complex formulation for the prevention or treatment of cardiovascular diseases, which comprises a) aspirin coated with a barrier containing a hydrophobic additive, and b) an HMG-CoA reductase inhibitor.
BACKGROUND OF THE INVENTION
Hyperlipidemia is the condition of abnormally elevated levels of lipids such as cholesterols, triglycerides, and others, in the plasma. Hyperlipidemia, particularly hypercholesterolemia, induces arterial thrombosis, resulting in arteriosclerosis which is thick accumulation of lipids within the blood vessel. It is clinically important since it contributes to cardiovascular diseases such as ischemic heart disease, angina pectoris, and myocardial infarction. The prevention of arteriosclerosis may be achievable by way of the treatment of hypercholesterolemia highly associated therewith.
For decades, HMG-CoA reductase inhibitors have been used to treat hyperlipidemia. Such compounds have been known to lower total cholesterol and LDL-cholesterol in human body and to elevate HDL-cholesterol in some individuals. They inhibit HMG-CoA reductase involved in the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol. This process increases receptors of LDLs which induce arteriosclerosis, leading to the decrease in the concentration of LDL within blood (Grundy S. M., N. Engl. J. Med., 319(l):24-32, 25-26, 31(1988). Examples of HMG-CoA reductase inhibitors include mevastatin (U.S. Pat. No. 3,983,140), lovastatin (also called mevinolin; U.S. Pat. No. 4, ,231,227), pravastatin (U.S. Pat. Nos. 4,346,227 and 4,410,629), pravastatin lactone (U.S. Pat. No. 4,448,979), velostatin (also called synvinolin; U.S. Pat. Nos. 4,448,784 and 4,450,171), simvastatin, rivastatin, fluvastatin, atorvastatin, rosuvastatin, cerivastain, and others.
Another mechanism leading to arteriosclerosis is thrombus formation. Thrombus is achieved via the interaction of platelets and plasma coagulation factor in an injured vessel, which also induces arteriosclerosis. Aspirin is used as an antipyretic to reduce fever, as an analgesic to relieve minor aches and pains, and as an agent to prevent arterial thrombosis. Aspirin (also known as acetylsalicylic acid) irreversibly acetylates cyclooxygenase, thereby inhibiting the production of thromboxane A2 (TXA2), which is synthesized by platelets to promote platelet aggregation. This blocks platelet aggregation in blood to decrease platelets.
The combination of an HMG-CoA reductase inhibitor and aspirin may be useful in treating various cardiovascular diseases by providing each effect of the drugs at the same time, as well as in treating a cardiovascular disease effectively by providing synergistic effects of the drugs. In addition, the complex formulation comprising the combination of said drugs may allow for greater ease of administration than the individual administrations of said drugs.
HMG-CoA reductase inhibitors exhibit poor bioavailability and are absorbed in the gastrointestinal tract, and thus it would be beneficial to be rapidly released in the gastrointestinal tract. Meanwhile, aspirin may exhibit adverse side effects, e.g., gastric ulcer or gastric bleeding when it is released within the gastrointestinal tract, and may interact adversely with HMG-CoA reductase inhibitors when both are released at the same time within the gastrointestinal tract. Thus, it needs to render aspirin to be released within not the stomach but the small intestine. The present inventors have filed an application for a formulation comprising an aspirin-containing granule and an HMG-CoA reductase inhibitor-containing granule (Korean Application Publication No. 2009-0030452). However, during storage, aspirin in the formulation degrades into salicylic acid by hydrolysis, and the resulting salicylic acid may degrade HMG-CoA reductase inhibitors which are unstable under acidic conditions.
The present inventors have found that the deterioration in the stability of HMG-CoA reductase caused by salicylic acid can be prevented by coating aspirin with a barrier containing a hydrophobic additive.
SUMMARY OF THE INVENTION Therefore, it is an object of the present invention to provide a complex formulation for the prevention or treatment of cardiovascular diseases, which has improved storage stability by preventing the deterioration in the stability of of HMG- CoA reductase inhibitors which is caused by salicylic acid. In accordance with one aspect of the present invention, there is provided a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor. Preferably, the barrier comprises the hydrophobic additive in an amount of 3.8-60% by weight based on the total weight of the barrier.
The complex formulation of the present invention exhibits excellent effect on the prevention and treatment of cardiovascular diseases, exerting improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase inhibitors which is caused by salicylic acid, thereby being useful for the prevention and treatment of cardiovascular diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, which respectively show:
Fig. 1 : the stability test of the complex formulation of the present invention after 4 months under accelerated conditions, showing the amounts of atorvastatin lactone and salicylic acid;
Fig. 2: the stability test of the complex formulation of the present invention after 4 months under accelerated conditions, showing the amounts of rosuvastatin lactone and salicylic acid;
Fig. 3: the stability test of the complex formulation of the present invention after 4 months under accelerated conditions depending on the amount of a hydrophobic additive, showing the amounts of atorvastatin lactone and salicylic acid;
Fig. 4: the dissolution rates of coated aspirin pellets of Examples 2 and 4, 'Aspirin Protect®', and 'Astrix®' for 1 hour depending on pH; and
Fig. 5: the change of dissolution rate of the complex formulation of the present invention for 1 hour depending on the amount of a hydrophobic additive.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing about 3.8-60% of a hydrophobic additive by weight based on the total amount of the barrier, as a 1st pharmacologically active ingredient; and b) an HMG- CoA reductase inhibitor as a 2nd pharmacologically active ingredient. Hereinafter, described are the properties and kinds of each ingredient consisting of the complex formulation of the present invention.
(i) 1st pharmacologically active ingredient (aspirin)
Aspirin is used as 1st pharmacologically active ingredient in the present invention so as to prevent and treat arterial thrombosis by blocking the platelet aggregation in blood. It may be employed in an amount of lOmg to 2g per the formulation and in the form of pellets or granules.
(ii) Hydrophobic additive (coating base)
A hydrophobic additive is used in the present invention so as to block the migration of salicylic acids into the granule layer containing an HMG-CoA reductase inhibitor, the use of which is different to enteric coating bases for releasing drugs depending on pH. When aspirin is coated with conventional coating bases, water- soluble and hydrophilic aspirin or salicylic acid derived from aspirin migrates to the coating layer, consequently penetrating the layer. But, when a hydrophobic additive is added to the coating layer, it is possible to prevent the migration of the drug to the coating layer and the consequent adverse influence of said drug on HMC-CoA reductase inhibitors. Such hydrophobic additive is a coating base which is irrelevant to pH and is not used for sustained- or delayed-release.
Examples of hydrophobic additives include waxes such as carnauba wax, glyceryl monostearate, glyceryl monooleate and beeswax; and synthetic or semisynthetic hydrophobic polymers such as ethyl cellulose, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer, polyvinyl chloride, polyvinyl acetate and cellulose acetate.
The barrier containing such hydrophobic additive may further comprise a plasticizer such as triethyl citrate, polyethylene glycol, propylene glycol, acetylated monoglyceride, diethyl phthalate and dibutyl sebacate, and may also comprise additional coating bases commonly used in pharmaceutical industry such as HPMC, HPC, polyvinyl alcohol, and others. In addition, talc, titanium dioxide, and others may be used to prevent the adhesion of pellets during coating procedure.
The hydrophobic additive may be used in an amount of about 3.8% or more by weight based on the total amount of the barrier, and it is preferred not to exceed about 60% by weight. When the amount exceeds 60% by weight based on the total amount of the barrier, the release of drug would be excessively delayed.
(iii) 2nd pharmacologically active ingredient (HMG-CoA reductase inhibitor) An HMG-CoA reductase inhibitor is used as a 2nd pharmacologically active ingredient so as to prevent or treat hyperlipidemia and arteriosclerosis by lowering the concentration of lipoproteins or lipids. Examples of HMG-CoA reductase inhibitors include mevastatin, rosuvastatin, atorvastatin, lovastatin, pravastatin, pravastatin lactone, pitavastatin, bervastatin, velostatin, simvastatin, rivastatin, fluvastatin, cerivastatin or isomers or salts and combinations thereof.
The HMG-CoA reductase inhibitor may be employed in an amount of 5mg to
80mg per the formulation and in the form of granules or pellets.
(iv) Enteric coating base
The complex formulation of the present invention may further comprise an enteric coating layer between the aspirin core and the hydrophobic barrier. The enteric coating base is not used for the purpose of preventing the interaction of the released salicylic acid and HMG-CoA reductase inhibitors. The effects of enteric coating base are not enough to inhibit the action of released salicylic acid as evidenced by the experiments of the present invention. The main objective of use of the enteric coating base is to allow aspirin to be released into not the stomach of a low pH but the small intestine, particularly the upper small intestine, of high pH. Examples of enteric coating bases include hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, methacrylic acid copolymer, and hydroxypropyl methylcellulose acetate succinate.
The coating base may be used in a weight ratio of 0.1 to 0.5 based on 1 weight of the core.
The complex formulation of the present invention may further comprise a stabilizing agent for enhancement stability of HMG-CoA reductase inhibitor, and examples of stabilizing agents include antioxidants such as tocopherol, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ascorbic acid and erythorbic acid; minerals such as CaC03, MgC03, NaHC03, KH2P04 and K2HP03; basic additives such as meglumine, arginine and glycine; and other stabilizing agents such as organic acids, e.g., citric acid and fumaric acid, or salts thereof.
The complex formulation of the present invention may be prepared by the method comprising: (1) preparing an aspirin granule or pellet which is coated with a barrier containing a hydrophobic additive; (2) preparing an HMG-CoA reductase inhibitor granule or pellet; and (3) filling a capsule with the aspirin granule or pellet and the HMG-CoA reductase inhibitor granule or pellet, prepared in steps (1) and (2), or compressing said granules or pellets.
Each process in the preparation of the complex formulation of the present invention may be carried out in accordance with conventional processes known in the pharmaceutical industry. The average diameter of the aspirin granule or pellet prepared in step (1) is preferably 1,200 μηι or less, more preferably 1,000 μηι or less. When the pellet size is bigger than 1,200 μπι, the mixing degree between both pharmacologically active ingredients become poor, which may adversely affect the homogeneity of the complex formulation in a form of tablets.
The present invention also provides a method of preventing or treating cardiovascular diseases, which comprises administering the complex formulation of the present invention to a mammal in need thereof.
The complex formulation of the present invention may be administered orally as an active ingredient in an effective amount ranging from about 0.01 to 100 mg/kg, preferably 0.2 to 50 mg/kg body weight per day in case of mammals including human in a single dose or in divided doses. The dosage of the active ingredient may be adjusted in light of various relevant factors such as the condition of the subject to be treated, type and seriousness of illness, administration rate, and opinion of doctor. In certain cases, an amount less than the above dosage may be suitable. An amount greater than the above dosage may be used unless it causes deleterious side effects and such amount can be administered in divided doses per day.
The following Examples are given for the purpose of illustration only, and are not intended to limit the scope of the invention. Example 1: Preparation of aspirin pellet and granule
<!-!> Preparation of aspirin pellet
In accordance with Table 1, aspirin (Spectrum Chemical, US), hydroxypropyl methylcellulose (HPMC; Shinetsu, Japan), citric acid and talc (Nippon talc, Japan) were dissolved and dispersed in a mixed solution of water and ethanol to prepare an aspirin-containing coating solution. The coating solution was sprayed while fluidizing microcrystalline spherical beads (cellet; Pharmatrans) using a fluidized bed spray coater (NQ-125, Fuji Paudal, Japan), to prepare an aspirin pellet.
<l-2> Preparation of aspirin granule
In accordance with Table 1 , aspirin, Avicel (FMC biopolymer, US), citric acid and mannitol were mixed and kneaded using hydroxypropyl methylcellulose (HPC) dissolved in water and ethanol, followed by extrusion using an extruder (MG-55, Dalton, Japan). Then, the extruded product was spheronized using a spheronizer (Q- 230T, Dalton, Japan) to obtain a spherical aspirin granule.
<Table 1>
Figure imgf000009_0001
Figure imgf000010_0001
Total weight 150mg 200mg
Examples 2 to 7; Coating with barrier containing hydrophobic additive (1)
In accordance with Table 2, the aspirin pellet or granule of Example 1 was coated with barriers containing various compositions of hydrophobic additives. Specifically, HPMC, acetylated monoglyceride (myvacet®; Kerry bio-science, US), talc, titanium dioxide (Ti02), and hydrophobic additives (camauba wax or ethyl cellulose (EC, Colorcon)) were dissolved and dispersed in a mixed solution of water and ethahol to prepare barrier coating solutions. Then, each coating solution was sprayed while fluidizing the aspirin pellet or granule (cellet; Pharmatrans) using a fluidized bed spray coater (NQ-125, Fuji Paudal, Japan), to prepare barrier-coated aspirin pellets.
<Table 2>
Figure imgf000010_0002
additive (%)
in coating bases
Comparative Examples 1 to 3: Conventional barrier or enteric coating
In order to prepare pellets or granules having a conventional barrier or enteric coating, the aspirin pellet or granule of Example 1 was coated with coating solutions shown in Table 3. Specifically, HPMC or HPMCP (hydroxypropyl methylcellulose phthalate; Shinetsu, Japan), Myvacet®, talc and titanium dioxide were dissolved and dispersed in a mixed solution of water and ethanol or acetone, to prepare barrier coating solutions. Then, the each coating solution was sprayed while fluidizing the aspirin pellet or granule of Example 1 using a fluidized bed spray coater (NQ-125, Fuji Paudal, Japan), to prepare conventional barrier-coated or enteric-coated aspirin pellets or granules.
<Table 3>
Figure imgf000011_0001
Example 8 and Comparative Example 4: Coating with barrier containing hydrophobic additive (2)
The pellets of Example <1-1> and Comparative Example 3 were coated with barriers containing a hydrophobic additive as shown in Table 4, respectively, according to same method with Exampl
<Table 4>
Figure imgf000012_0001
Example 9: Preparation of HMG-CoA reductase inhibitor granule
Granules containing various HMG-CoA reductase inhibitors were prepared.
<9-l> Preparation of atorvastatin-containing granule
In accordance with Table 5, atorvastatin calcium (TEVA, Israel) was mixed with Avicel®, croscarmellose sodium (DMV international), lactose(DMV international) and magnesium carbonate, and kneaded with a binding solution in which HPC and polysorbate 80 are dissolved in water. The combined product was dried, and sieved through a 30 mesh sieve to prepare an atorvastatin-containing granule.
<9-2> Preparation of rosuvastatin-containing granule
The procedure of Example <9-l> was repeated except for using rosuvastatin calcium (MSN, India) instead of atorvastatin calcium to obtain a rosuvastatin- containing granule.
<Table 5>
Figure imgf000013_0001
Formulation Examples 1 to 8 and Comparative Formulation Examples 1 to 7: Preparation of complex formulation containing aspirin/HMG-CoA reductase inhibitor
By the combinations of Examples and Comparative Examples above, complex formulations containing aspirin and HMG-CoA reductase inhibitor were prepared in accordance with Table 6. Specifically, granules (or pellets) corresponding to aspirin 100 mg and HMG-CoA reductase inhibitor 10 mg, respectively, were filled into size #0 capsules to obtain complex formulations. Comparative Formulation Examples 5 and 6 are formulations prepared by filling only HMC-CoA reductase inhibitors into size #0 capsules.
<Table 6>
Figure imgf000013_0002
Comp. Formul. Ex. 3 Comp. Ex. 3 Ex. <9-l>
Comp. Formul. Ex. 4 Comp. Ex. 3 Ex. <9-2>
Comp. Formul. Ex. 5 Ex. <9-l>
Comp. Formul. Ex. 6 Ex. <9-2>
Comp. Formul. Ex. 7 Ex. <1-1> Ex. <9-l>
Experimental Example 1: Stability test of formulations
The complex formulations prepared from Formulation Examples 1 to 8 and Comparative Formulation Examples 1 to 7 were each packaged together with lg of silica gel in an HDPE bottle and tested for their stability for 2 and 4 months by storing under accelerated conditions (45°C, 75% RH). In case of aspirin, the content of released salicylic acid was measured in accordance with the USP (United States Pharmacopeia) specification for 'aspirin tablet' and 'aspirin delayed-release capsule'. In case of atorvastatin, the contents of a representative acid hydrolyzate, i.e., atorvastatin lactone and total related compounds were measured. In case of rosuvastatin, the contents of rosuvastatin lactone and total related compounds were measured. The results are shown in Tables 7 and 8, and Figs. 1 to 3. Figs. 1 and 2 are graphs showing the stabilities after 4 months under accelerated conditions, and Fig. 3 is a graph showing the stability after 4 months under accelerated conditions depending on the amount of a hydrophobic additive.
<Table 7>
Figure imgf000014_0001
Figure imgf000015_0001
<Table 8>
Figure imgf000015_0002
Figure imgf000016_0001
As shown in Tables 7 and 8, it was confirmed that the content of salicylic acid increased with times, and there was no significant difference in the increase rate depending on the type of barrier bases. However, the production rates of salicylic acid and the occurrences of atorvastatin lactone and total related compounds were very high in Comparative Formulation Example 7 with no barrier. Hence, it was concluded that it would be preferable to separate said two pharmacologically active ingredients for stability improvement.
Meanwhile, Comparative Formulation Examples 1 and 2 using conventional coating bases, HPMC, and Comparative Formulation Example 3 using an enteric coating base, HPMCP, showed relatively stable appearances, but did not completely prevent the effects of released salicylic acid on an HMG-CoA reductase inhibitor. That is, salicylic acids released from aspirin hinder the stability of atorvastatin, and consequently its stability became poor compared to that of Comparative Formulation Example 5 using only atorvastatin. In particular, it was shown that much amounts of atorvastatin lactone and total related compounds were produced.
In addition, Formulation Examples 1 to 7 containing aspirin coated with EC or carnauba wax as a hydrophobic barrier showed highly improved stability than Comparative Formulation Examples. This indicates that salicylic acid penetrates conventional coating bases such as HPMC or HPMCP to affect an HMG-CoA reductase inhibitor, while it does not penetrate hydrophobic additives such as EC and carnauba wax not to affect the stability of atorvastatin. Such phenomenon was similarly observed in other HMG-CoA reductase inhibitor, rosuvastatin.
Thus, in a complex formulation containing aspirin and an HMG-CoA reductase inhibitor, it is considered that a complex formulation comprising ah aspirin granule coated with a hydrophobic additive-containing barrier can provide improved storage stability, such formulation being utilized as a stable and excellent agent for treating hypertension and hypercholesterolemia.
Experimental Example 2: Dissolution test of aspirin
The aspirin pellets of Examples 2 to 5 and Comparative Examples 1 and 4 were placed into capsules (e.g., gelation capsule; Capsugel) in an amount corresponding to lOOmg of aspirin, respectively, and tested for the dissolution in artificial gastric juice (pH 1.2) and in artificial enteric juice (phosphate buffer, pH 6.8) by 10 rpm according to USP apparatus 1 (basket). The analysis was carried out in accordance with the USP (United States Pharmacopeia) specification for 'aspirin tablet' and 'aspirin delayed-release capsule'. In addition, 'Aspirin Protect®' (Bayer, Germany) and 'Astrix®' capsule (Boryung, Korea), which are known to be released depending on pH due to their enteric coating, were subjected to the dissolution test in the same methods. The results are shown in Tables 9 and 10.
<Table 9>
Figure imgf000017_0001
15 61.2 55.5 47.1 32.5 3.5 60.2 22.4 32.1
30 95.4 88.4 76.5 52.4 9.5 94.2 62.3 58.8
60 99.3 97.8 95.7 83.4 22.2 95.7 94.3 88.7
120 97.7 98.9 97.9 97.7 42.3 95.5 93.6 94.3
<Table lO>
Dissolution (%) in pH 1.2
Time Ex. 2 Ex. 3 Ex. 4 Ex. 5 Comp. Comp. Aspirin Astrix (min) Ex. 4 Ex. 1 Protect
0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15 61.0 53.1 46.2 31.5 2.8 61.3 1.0 1.1
30 93.4 87.1 75.3 54.3 8.4 91.1 2.1 2.2
60 97.3 97.2 94.4 82.8 19.0 93.3 2.6 3.2
120 98.7 97.3 98.2 96.7 37:4 94.5 3.1 4.0
Fig. 4 was plotted based on the results of Tables 9 and 10. As shown in Fig. 4, the dissolution rates of 'Aspirin Protect®' and 'Astrix®' were significantly changed with pH, whereas the complex formulations of the present invention which contains aspirin coated with a hydrophobic additive-containing barrier showed no changes in dissolution rate with pH.
In addition, the dissolution rates of Examples 2 to 5 and Comparative Example 4 after 1 hour in pH 1.2 slowly decreased with the increase in amounts of hydrophobic additives, and its releases were dramatically delayed, in particular, when the amount of a hydrophobic additive exceeds 60%.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

What is claimed is:
1. A complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor.
2. The complex formulation of claim 1, wherein the amount of the hydrophobic additive is 3.8-60% by weight based on the total weight of the barrier.
3. The complex formulation of claim 1, wherein the hydrophobic additive is selected from the group consisting of carnauba wax, glyceryl monostearate, glyceryl monooleate, beeswax, ethyl cellulose, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer, polyvinyl chloride, polyvinyl acetate, cellulose acetate, and combinations thereof.
4. The complex formulation of claim 1, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of mevastatin, rosuvastatin, atorvastatin, lovastatin, pravastatin, pravastatin lactone, pitavastatin, bervastatin, velostatin, simvastatin, rivastatin, fluvastatin, cerivastatin, and isomers, salts and combinations thereof.
5. The complex formulation of claim 1, wherein the amount of the HMG-CoA reductase inhibitor is 5 to 80 mg.
6. The complex formulation of claim 1, wherein the amount of the aspirin is 10 mg to 2 g.
7. The complex formulation of claim 1, which further comprises a stabilizing agent for the improvement of the stability of HMG-CoA reductase inhibitor.
8. The complex formulation of claim 7, wherein the stabilizing agent is selected from the group consisting of antioxidants, minerals, basic additives, and organic acids and salts thereof.
9. The complex formulation of claim 8, wherein the antioxidant is tocopherol, butylated hydroxytoluene(BHT), butylated hydroxyanisole(BHA), ascorbic acid or erythorbic acid, the mineral is CaC03, MgC03, NaHC03, KH2P04 or K2HP03, the basic additive is meglumine, arginine or glycine, and the organic acid is citric acid or fumaric acid.
10. The complex formulation of claim 1, wherein each of the aspirin and the HMG-CoA reductase is formulated into a pellet or a granule.
11. The complex formulation of claim 1, which further comprises an enteric- coated layer between the aspirin and the barrier.
12. The complex formulation of claim 11, wherein the enteric coating is hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, methacrylic acid copolymer, or hydroxypropyl methylcellulose acetate succinate.
13. The complex formulation of claim 12, wherein the weight ratio of the enteric coating is 0.1 to 0.5 based on 1 weight of the core.
14. A use of the complex formulation of claim 1 for the manufacture of a medicament for preventing or treating cardiovascular diseases.
PCT/KR2011/000541 2010-02-02 2011-01-26 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor WO2011096665A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2012551908A JP2013518873A (en) 2010-02-02 2011-01-26 Composite formulation comprising aspirin coated with a barrier containing a hydrophobic additive and an HMG-CoA reductase inhibitor
CN2011800078123A CN102740857A (en) 2010-02-02 2011-01-26 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor
EP11739961.8A EP2531199A4 (en) 2010-02-02 2011-01-26 COMPLEX FORMULATION COMPRISING ASPIRINE COATED WITH A BARRIER CONTAINING A HYDROPHOBIC ADDITIVE, AND A HMG-COA REDUCTASE INHIBITOR
US13/576,585 US20120301549A1 (en) 2010-02-02 2011-01-26 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100009636A KR101193493B1 (en) 2010-02-02 2010-02-02 Composite formulation comprising aspirin coated with barrier containing water-insoluble additive and HMG-CoA reductase inhibitor
KR10-2010-0009636 2010-02-02

Publications (2)

Publication Number Publication Date
WO2011096665A2 true WO2011096665A2 (en) 2011-08-11
WO2011096665A3 WO2011096665A3 (en) 2012-01-05

Family

ID=44355918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000541 WO2011096665A2 (en) 2010-02-02 2011-01-26 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor

Country Status (8)

Country Link
US (1) US20120301549A1 (en)
EP (1) EP2531199A4 (en)
JP (1) JP2013518873A (en)
KR (1) KR101193493B1 (en)
CN (1) CN102740857A (en)
AR (1) AR080023A1 (en)
TW (1) TW201141487A (en)
WO (1) WO2011096665A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002919A1 (en) * 2010-06-30 2012-01-05 Mahmut Bilgic Pharmaceutical formulations comprising atorvastatin and aspirin
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240429B1 (en) * 2013-05-06 2021-04-15 한미약품 주식회사 Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
JP2020507621A (en) * 2017-01-23 2020-03-12 ドン ファ ファーマシューティカル カンパニー リミテッド Complex preparation containing HMG-CoA reductase inhibitor and clopidogrel
WO2023204397A1 (en) * 2022-04-19 2023-10-26 한미약품 주식회사 Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
KR100646576B1 (en) * 2005-02-15 2006-11-23 한국유나이티드제약 주식회사 Combined Pellets Containing HMG-CO Reductase Inhibitor and Enteric-Coated Aspirin for Prevention of Atherosclerosis in Patients with Hyperlipidemia
US20120015032A1 (en) * 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
KR20090030452A (en) * 2007-09-20 2009-03-25 한미약품 주식회사 Complexes containing HMV-COA Reductase Inhibitors and Aspirin
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2531199A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002919A1 (en) * 2010-06-30 2012-01-05 Mahmut Bilgic Pharmaceutical formulations comprising atorvastatin and aspirin
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2014195421A1 (en) * 2013-06-06 2014-12-11 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
EP2986281B1 (en) 2013-06-06 2016-12-21 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
AU2014276883B2 (en) * 2013-06-06 2017-04-20 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
EP3175849A1 (en) 2013-06-06 2017-06-07 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
MD4475C1 (en) * 2013-06-06 2017-11-30 Ferrer Internacional, S.A. Use of an oral formulation for the treatment of cardiovascular diseases
EA028969B1 (en) * 2013-06-06 2018-01-31 Феррер Интернасионал, С.А. Method for the prevention and/or treatment of cardiovascular diseases
US10617699B2 (en) 2013-06-06 2020-04-14 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
EP2531199A2 (en) 2012-12-12
CN102740857A (en) 2012-10-17
WO2011096665A3 (en) 2012-01-05
EP2531199A4 (en) 2013-07-10
KR20110090060A (en) 2011-08-10
KR101193493B1 (en) 2012-10-22
US20120301549A1 (en) 2012-11-29
TW201141487A (en) 2011-12-01
JP2013518873A (en) 2013-05-23
AR080023A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
CN101090718B (en) Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same
CN108366957A (en) Lucky Cabbeen for treating angiocardiopathy combines
EP1905424A2 (en) Pharmaceutical composition comprising stabilized statin particles
KR20120109950A (en) Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
MX2010010479A (en) Capsule for the prevention of cardiovascular diseases.
CA2994073A1 (en) Tablet comprising a core of acetylsalicylic acid with enteric coating and an outer layer with a potassium-competitive acid blocker
JP2015522653A (en) Pharmaceutical composition of proton pump inhibitor
US20120301549A1 (en) Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor
WO2009010810A2 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
JP2009521526A (en) Combined preparation containing amlodipine cansylate and simvastatin and method for producing the same
US20130243872A1 (en) Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
WO2013123965A1 (en) A fixed dose pharmaceutical formulation
JP2005538097A (en) Composition comprising an HMG-COA reductase inhibitor
CA2912350C (en) Oral formulation for the treatment of cardiovascular diseases
EP2780002A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
KR102139346B1 (en) COMPLEX PREPARATION COMPRISING HMG-CoA REDUCTASE AND CLOPIDOGREL
KR20090030452A (en) Complexes containing HMV-COA Reductase Inhibitors and Aspirin
KR101830977B1 (en) Oral complex formulation comprising omega-3 fatty acid or ester thereof and HMG-CoA reductase inhibitor
KR101950907B1 (en) Oral preparation comprising liphophilic drug and a oilproof material coated solid formulation
KR101072600B1 (en) Stable pharmaceutical composition comprising fluvastatin and method for preparing the same
KR20130003501A (en) Oral complex formulation comprising omega-3 fatty acid or ester thereof and hmg-coa reductase inhibitor
HK1111903A (en) Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180007812.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11739961

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012551908

Country of ref document: JP

Ref document number: 13576585

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011739961

Country of ref document: EP